Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Key Patent Granted For AAVLife’s Gene-Therapy Program to Treat Cardiomyopathy in Friedreich’s Ataxia

 

"As this recently issued patent indicates, AAVLife is building strong intellectual-property protection at the same time we are steadily progressing our R&D toward an urgently needed therapy,” said Amber Salzman, Chief Executive Officer of AAVLife.

Read More:  Key Patent Granted for AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's ataxia

SHARE

FacebookTwitterLinkedInYoutube
michelle-h.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News


Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator